The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune-Mediated Inflammatory Disease.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy（2023）
摘要
This trial is registered with ClinicalTrials.gov: NCT04089514.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要